Position in EXEL
as of Jun 30, 2026
· filed Jul 15, 2026
Position Value
$872,137
-$35,329 QoQ
Shares Held
16,029
-24.2% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#19
of 61 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Brookstone Capital Management holds $3,313,596 across 9 Biotechnology names. EXEL ranks #2 (26.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TGTX |
Tg Therapeutics, Inc.
|
17,521 | $962,603 | |
| 2 | EXEL |
Exelixis, Inc.
This page
|
16,029 | $872,137 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
11,032 | $863,474 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
500 | $248,365 | |
| 5 | URGN |
UroGen Pharma Ltd.
|
6,000 | $220,800 | |
| 6 | IOVA |
Iovance Biotherapeutics, Inc.
|
22,607 | $94,045 | |
| 7 | BDTX |
Black Diamond Therapeutics, Inc.
|
13,484 | $24,945 | |
| 8 | GUTS |
Fractyl Health, Inc.
|
21,272 | $16,889 |
All Filings in EXEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $872,137 | 16,029 | Shares | Sole | 2026-07-15 | |
| 2026-03-31 | $907,466 | 21,158 | Shares | Sole | 2026-04-16 | |
| 2025-12-31 | $704,874 | 16,082 | Shares | Sole | 2026-01-15 | |
| 2025-09-30 | $661,460 | 16,016 | Shares | Sole | 2025-10-15 | |
| No filing history on record for this holder in this stock. | ||||||